ArticleClinical and experimental immunology1997
IgA nephropathy-specific expression of the IgA Fc receptors (CD89) on blood phagocytic cells.
Article in Clinical and experimental immunology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 28 citations in OpenAlex.
- The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis.Frontiers in immunology · 2023Review
- Portrait of Tissue-Specific Coexpression Networks of Noncoding RNAs (miRNA and lncRNA) and mRNAs in Normal Tissues.Computational and mathematical methods in medicine · 2019Article
- Discovery of a novel splice variant of Fcar (CD89) unravels sequence segments necessary for efficient secretion: A story of bad signal peptides and good ones that nevertheless do not make it.Cell cycle (Georgetown, Tex.) · 2017Article
- IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential.Springer seminars in immunopathology · 2006Article
- Progress in molecular and genetic studies of IgA nephropathy.Journal of clinical immunology · 2001Review
- Oligoclonally expanding gammadelta T lymphocytes induce IgA switching in IgA nephropathy.Clinical and experimental immunology · 2001Article
- Immunoglobulin-binding sites of human FcalphaRI (CD89) and bovine Fcgamma2R are located in their membrane-distal extracellular domains.The Journal of experimental medicine · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We analysed the biochemical features of receptors for the Fc-region of IgA (Fc alphaR, CD89) on blood monocytes and granulocytes of patients with IgA nephropathy (IgAN). Fc alphaR on monocytes of IgAN were found to have a higher Mr (60-80 kD) than those of control monocytes (50-75 kD) and granulocytes (55-75 kD) in both IgAN and controls as shown by immunoprecipitation analysis. Removal of N-linked carbohydrates from Fc alphaR on monocytes of IgAN revealed a 32-36 kD protein core, the Mr of which was still higher than that of controls (28-32 kD). When Fc alphaR transcripts were analysed by reverse-transcription-PCR, only one prominent band was visualized in PCR products from IgAN monocytes. Since the results thus far show that IgAN monocytes express Fc alphaR protein and mRNA differently from granulocytes and control monocytes, PCR products were then cloned and sequenced. The predominant band in PCR products from IgAN monocytes was identical to that of the Fc alphaR a.1 transcript, and an additional 10 transcripts containing five novel transcripts were obtained from granulocytes and control monocytes. In three transcripts, we found an insertion sequence between the S2 and EC1 domains, suggesting the existence of a new exon. These results suggest a predominant usage of Fc alphaR a.1 among various transcripts of Fc alphaR in IgAN monocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.